IN Brief:
- Sibel Health has secured $3.5m from ARPA-H to develop a wearable edema monitoring sensor.
- The device will target continuous, objective lower-leg edema tracking beyond the clinic.
- Medical wearable design is moving toward condition-specific sensing, clinical-grade data, and remote monitoring workflows.
Sibel Health has received a $3.5m Direct-to-Phase II Small Business Innovation Research contract from the Advanced Research Projects Agency for Health to develop a wearable monitor for continuous lower-leg edema assessment.
The project will develop an ambulatory edema monitor for tracking lower-leg swelling outside a clinical examination room. The proposed multi-modality biosensor patch is intended to replace subjective manual assessment with continuous monitoring data that can support clinical decision-making.
Edema, the pathological accumulation of fluid in tissue, is associated with multiple conditions including breast cancer, venous insufficiency, and congestive heart failure. In heart failure, lower-leg swelling can indicate clinical deterioration. Standard edema assessment still relies on a clinician pressing a finger into the patient’s skin and grading the indentation on a four-point scale.
The new project moves beyond basic wearable vital-sign capture. Continuous ambulatory edema monitoring requires hardware, sensing, signal processing, and clinical validation to work together in a device that can be worn outside formal care settings. The sensor must detect clinically meaningful tissue changes while managing motion artefacts, skin contact variation, power consumption, comfort, and data reliability.
Steve Xu, MD, CEO of Sibel Health and principal investigator, said: “ARPA-H is making the kinds of investments in health research and development that the private sector alone will not make — especially when the technology risk is high and the unmet clinical needs have been underserved. We are deeply grateful to ARPA-H for selecting Sibel and our team to execute on this program.”
Sibel Health already develops FDA-cleared wearable biosensor platforms for continuous physiological monitoring. Its portfolio includes the ANNE One wireless monitoring system for paediatric and adult monitoring, and ANNE Maternal for maternal-fetal monitoring. That platform base gives the edema project a route into mobile software, cloud infrastructure, and clinical monitoring workflows rather than leaving the sensor as a standalone hardware concept.
Medical electronics is moving from general wellness monitoring toward targeted clinical sensing. Heart rate, blood oxygen, movement, and temperature are now common wearable data streams. The next stage requires devices that can measure condition-specific signals with enough accuracy, repeatability, and clinical relevance to influence care decisions. That places greater demands on sensor physics, materials, firmware, analytics, regulatory planning, and workflow integration.
Lower-limb edema is a demanding use case for that shift. A wearable patch must distinguish fluid-related changes from variation caused by posture, movement, compression, temperature, and tissue response. It also has to work in patient populations that may have fragile skin, limited mobility, or multiple co-morbidities. The device therefore has to function as both a measurement system and a practical medical product.
Remote monitoring technologies also need to fit into clinical operating models. Data from a wearable sensor only becomes useful when it can be interpreted, triaged, and acted on without overwhelming care teams. Continuous edema monitoring will require reliable thresholds, usable alerts, secure data transfer, and integration into chronic disease management workflows.
The ARPA-H contract gives Sibel Health funding to advance the sensing, signal-processing, and validation work needed to turn lower-leg edema monitoring into a wearable clinical tool.
